COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,051 Articles (22,627 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 1756: Articles 17551-17560  | Next

Critical COVID-19 represents an endothelial disease with high similarity to kidney disease on the molecular level
Siwy, J., Wendt, R., Albalat, A., He, T., Mischak, H., Mullen, W., Latosinska, A., Luebbert, C., Kalbitz, S., Mebazaa, A., Peters, B., Stegmayr, B., Spasovski, G., Wiech, T., Staessen, J., Wolf, J., Beige, J.
10.1101/2021.02.22.21252207 — Posted: 2021-02-23
A cross-sectional study of socioeconomic status and treatment interruption among Japanese workers during the COVID-19 pandemic
Fujimoto, K., Ishimaru, T., Tateishi, S., Nagata, T., Tsuji, M., Eguchi, H., Ogami, A., Matsuda, S., Fujino, Y.
10.1101/2021.02.22.21252190 — Posted: 2021-02-23
A monocyte/dendritic cell molecular signature of SARS-CoV2-related multisystem inflammatory syndrome in children (MIS-C) with severe myocarditis
de Cevins, C., Luka, M., Smith, N., Meynier, S., Magerus, A., Carbone, F., Garcia Paredes, V., Barnabei, L., Batignes, M., Boulle, A., Stolzenberg, M.-C., Perot, B. P., Charbit, B., Fali, T., Pirabarakan, V., Sorin, B., Riller, Q., Abdessalem, G., Beretta, M., Grzelak, L., Goncalves, P., Di Santo, J. P., Mouquet, H., Schwartz, O., Zarhrate, M., Parisot, M., Bole-Feysot, C., Masson, C., Cagnard, N., Corneau, A., Bruneau, C., Zhang, S.-Y., Casanova, J.-L., Bader Meunier, B., Haroche, J., Melki, I., Lorrot, M., Oualha, M., Moulin, F., Bonnet, D., Belhadjer, Z., Leruez, M., Allali, S., Gras Leguen, C., de Pontual, L., Fischer, A., Duffy, D., Rieux-Laucat, F., Toubiana, J., Menager, M. M.
10.1101/2021.02.23.432486 — Posted: 2021-02-23
At the Intersection Between SARS-CoV-2, Macrophages and the Adaptive Immune Response: A Key Role for Antibody-Dependent Pathogenesis But Not Enhancement of Infection in COVID-19
DeMarco, J. K., Severson, W., DeMarco, D., Pogue, G., Gabbard, J. D., Palmer, K. E.
10.1101/2021.02.22.432407 — Posted: 2021-02-23
Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection.
Ma, L., Sahu, S. K., Cano, M., Kuppuswamy, V., Bajwa, J., McPhatter, J., Pine, A. B., Meizlish, M. M., Goshua, G., Chang, C. H., Zhang, H., Price, C., Bahel, P., Rinder, H. M., Lei, T., Day, A., Reynolds, D., Wu, X., Schriefer, R., Rauseo, A. M., Goss, C. W., O'Halloran, J. A., Presti, R. M., Kim, A. H., Gelman, A. E., Dela Cruz, C. S., Lee, A. I., Mudd, P. A., Chun, H. J., Atkinson, J. P., Kulkarni, H. S.
10.1101/2021.02.22.432177 — Posted: 2021-02-23
SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques
Philippens, I. H. C. H. M., Boszormenyi, K. P., Wubben, J. A., Fagrouch, Z. C., van Driel, N., Mayenburg, A. Q., Lozovagia, D., Roos, E., Schurink, B., Bugiani, M., Bontrop, R. E., Middeldorp, J., Bogers, W. M., de Geus-Oei, L.-F., Langermans, J. A. M., Stammes, M. A., Verstrepen, B. E., Verschoor, E. J.
10.1101/2021.02.23.432474 — Posted: 2021-02-23 Discussion: Onsite
A rapid review of equity considerations in large-scale testing campaigns during infectious disease epidemics
Ost, K., Duquesne, L., Duguay, C., Traverson, L., Mathevet, I., Ridde, V., Zinszer, K.
10.1101/2021.02.22.21252205 — Posted: 2021-02-23
Estimating the spreading and dominance of SARS-CoV-2 VOC 202012/01 (lineage B.1.1.7) across Europe
Gozzi, N., Chinazzi, M., Davis, J. T., Mu, K., Pastore y Piontti, A., Ajelli, M., Perra, N., Vespignani, A.
10.1101/2021.02.22.21252235 — Posted: 2021-02-23
Factors Associated with Timely Test Seeking, Test Turnaround, and Public Reporting of COVID-19: a retrospective analysis in Ontario, Canada
Joh, E., Buchan, S. A., Daneman, N., Paul, L. A., Brown, K. A.
10.1101/2021.02.22.21252219 — Posted: 2021-02-23
Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach
Nogueira Vilches, T., Rubio, F. A., Forti Perroni, R., Berg de Almeida, G., Pio Ferreira, C., Fortaleza, C. M. C. B.
10.1101/2021.02.22.21252208 — Posted: 2021-02-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).